Neuro-Sys is pioneering R&D into neurodegenerative diseases by supplying the latest generation of preclinical models and drug discovery services to accelerate therapies. Between France and America, the company applies its mission to solving the multisided complexities of neurological diseases, including things like neuro-degeneration, with particular emphasis on issues like Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and peripheral neuropathies.

Neuro-Sys is founded in 2013, working with both facilities in France and the USA. The clear understanding of the central nervous and peripheral nervous systems (CNS and PNS) has placed this company straightforwardly ahead of the call on advance. The company's advancement in scientific research, utilizing sophisticated in-vitro models, draws from that deep expertise in neurodegenerative disease mechanisms to much avail.

Neuro-Sys believes that it could create innovative drug discovery paradigms through the understanding of intrinsic pathways behind neuronal demise and the progressive nature of these diseases. Neuro-Sys has focused on research and development with an aim of accelerating efforts on effective treatments for some of the toughest neurological disorders.

Advanced Preclinical Models by Neuro-Sys

Neuro-Sys has advanced their state of the art preclinical models in ways that offer significant translational utility to understand the pathogenesis of neurodegenerative diseases. The three-dimensional preclinical model is really nice with regard to the disease mechanism evaluation and assessment in possible therapeutic intervention. 

Blood Brain Barrier (BBB) Model in three dimensions

NeuroSys developed a state of the art Three Dimensions Blood Brain Barrier (BBB) model to characterize permeability of compounds across the brain barrier. The human brain physiology is reproduced by this model and is used to find out if the drug can pass this barrier to treat nervous system disorders. The model helps make pre-assessment better for drug development and more efficient, thereby reducing risk of failure in later development phases.

Alzheimer’s disease (AD) Model

The model of Alzheimer’s disease is available in Neuro-Sys and models the pathology associated with this difficult neurodegenerative disease. To duplicate features that are similar to AD, including amyloid beta plaques and tau tangles, researchers can study the create progression of the disease and possible therapeutic strategies.

Parkinson’s disease (PD) Model

Neuro-Sys's model for Parkinson's disease (PD) recreates specific degeneration processes in dopaminergic neurons that are characteristic of Parkinson's pathology. The PD model also simulates motor deficits, as well as neuronal loss so as to provide a platform for assessing the effectiveness of treatments either symptomatically or in reversing neuronal damage. This permits measuring the effects of treatment on motor function, dopaminergic neurotransmission, and survival of neurons, all of which are to augment therapy aimed at improving the patient's future.

Impact on Drug Discovery and Neuroscience

Neuro-Sys is advancing drug discovery through BBB, AD, and PD models, improving understanding and treatment of neurodegenerative disorders. Their innovative research is fast-tracking studies in targeted therapies for complex neurological conditions, offering hope to patients with untreatable diseases. Neuro-Sys leads in breakthroughs and patient care in the field of neurodegenerative disease research. 

About the Leader

Dr. Noelle Callizot, Co-founder and Chief Scientific Officer of Neuro-Sys, has more than 20 years of experience in neurodegenerative disease research and neuro-active molecules.

“Driving Neurodegenerative Disease Research Innovation to Shovel to a Healthier Future.”